[Solved] What makes psilocybin therapy effective?

The effectiveness of psilocybin therapy stems from a unique combination of biochemical, psychological and neurological effects. Triptherapie emphasises that psilocybin not only provides a profound mind-expanding experience, but also causes structural changes at a cellular level that facilitate recovery from a wide range of conditions such as depression, trauma, anxiety, addiction and even chronic inflammation.

From a biochemical perspective, psilocybin stimulates the production of BDNF (Brain-Derived Neurotrophic Factor), which leads to improved brain plasticity and the formation of new neural connections. At the same time, it inhibits inflammatory processes, reduces stress hormones such as cortisol and activates SIRT1 – an enzyme that promotes DNA repair and protects telomeres. These effects ensure that the body and mind are literally 'reset' at a deeper level.

Psychologically, psilocybin is effective because it temporarily suppresses the Default Mode Network. This brain network is often overactive in people with depression, ruminative thoughts and trauma. During a session, this can help break through fixed patterns of thinking, creating space for new insights, emotional processing and acceptance.

Out experiences on the forum It appears that psilocybin also aids self-reflection, helps to let go of fears and enables people to rediscover a sense of purpose – something that many clients find healing. The intensity of the emotions released during a session can lead to catharsis and the feeling of ‘finally being connected with yourself again’.

Finally, the support provided by Triptherapie is crucial to its effectiveness. The sessions are tailored to your biochemistry, mental state and goals. We use dietary advice, supplements, aromatherapy and integration sessions to ensure the experience is not only intense but also sustainable. Would you like to get started? Then take the intake for psychedelic therapy to find out which approach suits you best.

Psilocybin therapy – the supervised administration of the psychedelic substance psilocybin, often in combination with psychotherapy – is showing promising results for conditions such as depression, anxiety and post-traumatic stress disorder (PTSD). What is unique about this therapy is that a single session or a few sessions with psilocybin can lead to long-term symptom relief. However, the precise mechanisms of action are still being investigated. This report highlights two key aspects: (1) Emotional processing and the process of letting go, including how psilocybin helps people to cope with anxiety, grief and trauma, and (2) Neurobiological and biochemical effects, focusing on Sirtuin-1 (SIRT1), Brain-Derived Neurotrophic Factor (BDNF), pancreatic β-cells and other relevant molecular pathways. We discuss how these processes contribute to the effectiveness of psilocybin therapy, supported by recent scientific findings (from 2020 onwards).

Emotional processing and letting go of fear, grief and trauma

Psilocybin therapy is known to elicit profound emotional experiences that help patients work through and “let go” of repressed feelings. In traditional therapies, patients often avoid their painful emotions (“experiential avoidance”), which hinders healing. Under the influence of psilocybin, however, a shift occurs from avoidance to acceptance: clients can allow themselves to experience difficult inner feelings without running away from them. Under controlled conditions, this acceptance leads to the processing of fear, grief and trauma, which may be accompanied by emotional breakthroughs – intense cathartic experiences that are of great therapeutic value.

During a psilocybin session, patients are often advised to surrender to the experience rather than resist it. Research confirms that “letting go” or “surrender” during difficult moments is crucial to a positive therapeutic outcome. Patients regularly report that a challenging trip only turns into something positive when they stop fighting it and open themselves up completely to their emotions – in other words, when they feel they are vomit or to let it go. This attitude of acceptance during the acute experience fosters what are known as emotional breakthroughs, in which pent-up fear, sadness or trauma is released through, for example, crying, forgiveness or deep insight. In retrospect, such breakthroughs are often cited as turning points towards recovery and improved well-being.

At a neurological level, psychedelics appear to induce a state in the brain that facilitates the processing of emotions. For example, it has been shown that psilocybin amygdala – the area of the brain involved in fear responses – less reactive to negative stimuli. This dampening of excessive fear responses means that patients can confront traumatic memories without immediately going into defence mode or panicking. In a clinical context, this translates into reliving traumatic events with a new sense of safety, allowing the memories to be “rewritten”, as it were (memory reconsolidation), in less threatening terms. In addition, psychedelics temporarily disrupt the normal, rigid patterns in brain networks such as the default mode network (DMN), which is often hyperactive in depression and PTSD and perpetuates entrenched negative thought patterns. Psilocybin breaks through this rigidity and increases cognitive flexibility, helping patients to develop new perspectives on themselves and their trauma. Together, these effects – emotional release, reduced anxiety response and increased brain plasticity – help patients to cope with anxiety, grief and trauma to let go and to integrate it, which underlies the significant improvements in symptoms observed in studies.

Neurobiological and biochemical effects of psilocybin

In addition to psychological effects, psilocybin triggers a cascade of neurobiological and biochemical changes that make the therapy more effective. Key factors in this regard are SIRT1, BDNF, β-cells and other molecular pathways, such as serotonin receptors and inflammatory markers.

SIRT1 and cellular health

Sirtuin-1 (SIRT1) is an enzyme that plays a role in cellular metabolism, the stress response and ageing. Recent research suggests that psilocybin activates this ‘longevity’ protein. In a preclinical study, exposure of cells to psilocin (the active metabolite of psilocybin) led to increased expression of SIRT1. This was accompanied by signs of improved cellular health: reduced DNA damage (lower GADD45a levels) and reduced oxidative stress. Remarkably, in this study, psilocin significantly extended the lifespan of cells (by 29–57%) and maintained telomere length compared with control cells. Evidence has also been found in living organisms: older mice that received a low monthly dose of psilocybin for 10 months lived longer than untreated mice. One possible explanation is that activation of SIRT1 makes cells more resilient to stress and ageing, which could benefit both physical and mental health. Although this “anti-ageing” effect of psilocybin is still in the early stages of research, it illustrates that psilocybin therapy may have a broader effect than just on the brain – it may bring the whole body into a healthier, more resilient state. A more resilient brain and body may recover better from the damage caused by chronic stress and depression, which could explain the long-lasting therapeutic effects of a single psilocybin treatment.

BDNF and neuroplasticity

One of the most widely studied effects of psilocybin is the increase in Brain-Derived Neurotrophic Factor (BDNF), a growth factor that is crucial for neuroplasticity and brain cell survival. Lower BDNF levels are associated with depression and anxiety, whilst higher BDNF levels are linked to recovery and resilience. Psilocybin appears to be a powerful stimulator of BDNF: increases in BDNF have been measured following psilocybin administration in both animals and humans. In a clinical trial, it was observed that a single high dose of psilocybin increased the peak concentration of BDNF in the blood – regardless of whether patients had previously been treated with an SSRI (escitalopram) or not. This suggests that psilocybin has a direct and potent effect on BDNF production. BDNF promotes the formation of new connections between neurons and supports neurogenesis (the creation of new brain cells). Animal studies confirm that psilocybin stimulates the formation of new neurons: in rats, psilocybin increased neurogenesis in the hippocampus (which is important for learning and memory), with higher doses having a greater effect. Also in vitro It has been shown that psilocybin can promote neuronal growth and the formation of connections.

A groundbreaking study in 2023 even uncovered an entirely new mechanism: psilocin appears to direct to link to the TrkB-receptor, the receptor to which BDNF normally binds. In other words, psilocybin’s metabolite acts as a positive allosteric modulator of the BDNF receptor. This results in enhanced BDNF signalling pathways and associated synaptic plasticity, independent of classical serotonin 5-HT₂A receptor activation. In mice, it was demonstrated that the antidepressant and neuron-growth-promoting effects of psilocin required TrkB/BDNF signalling pathways to be active – if TrkB was blocked, these benefits disappeared. This finding highlights the importance of BDNF: psilocybin therapy works in part by putting the brain into a growth mode, similar to (but more potent than) conventional antidepressants. By increasing BDNF levels and activating TrkB, psilocybin helps the brain’s neural network to form new, healthier patterns. This may explain why clients often speak of “entrenched” patterns of thought and behaviour being broken following a psilocybin experience – the increased neuroplasticity allows new insights and behavioural changes to take root. Together with the therapeutic setting, this neurobiological “rewiring” ensures that emotional breakthroughs and insights are transformed into lasting psychological improvements.

Effects on β-cells and metabolism

It is noteworthy that psilocybin may also have effects outside the nervous system, for example on metabolism. Recent research suggests that pancreatic β-cells – the insulin-producing cells – possess serotonin receptors and can therefore be affected by psilocybin. In a laboratory study (2024), isolated rat β-cells were exposed to psilocybin and subsequently to a diabetes-like stressor (high glucose and fat concentrations). The results were promising: β-cells that had been administered psilocybin survived significantly better than untreated cells under these harmful conditions. Psilocybin was found to protect against stress-induced cell death (apoptosis) – it reduced the activation of key apoptotic proteins and caspase enzymes in those cells. In addition, psilocybin slowed down the process of dedifferentiation, whereby mature β-cells revert to a less functional, immature state. This means that psilocybin was better able to preserve the identity and survival of the insulin-producing cells despite the severe metabolic stress. It was notable that, in this model, psilocybin did not immediately restore the already reduced insulin secretion under high blood sugar levels – it protects the cells, but does not acutely improve their function in such a stressful situation. Nevertheless, these findings suggest that microdosing with psilocybin or psilocybin analogues may preventative could be beneficial for people with metabolic syndrome or early-stage diabetes. By inhibiting β-cell loss, psilocybin could, in theory, slow the progression of diabetes, although further research in animals and humans is needed to confirm this. This unexpected biochemical This mechanism of action illustrates that psilocybin has a broad spectrum of effects: it affects not only the brain and psyche, but possibly also peripheral organs via the serotonin system. Physical and mental health are intertwined; for example, depression is often accompanied by chronic inflammation and metabolic dysfunction. By protecting β-cells and perhaps reducing metabolic stress, psilocybin could indirectly contribute to a healthier balance in the body, which in the long term would also benefit mood and cognitive function. Although these applications are still speculative, they open the door to psilocybin as a potential holistic a medicine that improves both the mental and physical aspects of wellbeing.

Other molecular mechanisms and biomarkers

As a classic psychedelic, psilocybin primarily affects the serotonin 5-HT₂A receptor in the brain. This activation triggers many of the processes discussed above. For example, 5-HT₂A agonism acutely leads to increased glutamate release in the prefrontal cortex, which in turn stimulates the release of BDNF and thus promotes neuroplasticity. Interestingly, following the initial stimulation, a downregulation of 5-HT₂A receptors occurs, which may play a role in the antidepressant after-effects of psilocybin (similar to the mechanism of classical antidepressants, but much faster). In addition, psilocybin also affects other serotonin receptors (such as 5-HT₁A), which are involved in regulating stress hormones and mood.

Another relevant biological pathway is the immune modulation by psilocybin. Chronic inflammation is associated with depressive symptoms, and a significant proportion of patients with depression show elevated levels of inflammatory markers (such as IL-6, TNF-α and C-reactive protein). Preclinical studies suggest that serotonergic psychedelics may mitigate inflammatory responses. For example, the production of pro-inflammatory cytokines (e.g. IL-6 and TNF-α) in human cells decreased following exposure to DMT, 5-MeO-DMT and LSD or psilocybin. Also in in vivo Studies involving ayahuasca (which contains DMT) have shown shifts in immune cells towards a less inflammatory profile. By dampening inflammation and oxidative stress (to which SIRT1 activation is also likely to contribute), psilocybin may reduce the toxic impact of inflammation on the brain, thereby paving the way for recovery and neuroplasticity.

Finally, neuroimaging research has shown that psilocybin brain connectivity reorganised in a unique way. During the acute trip, networks such as the DMN are temporarily disorganised, whilst functional connections between previously separate networks actually increase. This “reset” of networks is accompanied by phenomena such as ego dissolution (the temporary loss of a strict sense of self) and the emergence of new perspectives. After the experience, connectivity returns to normal, but often with a beneficial effect: in patients with depression, for example, it has been found that following psilocybin therapy, hyperconnectivity within the DMN decreases, which correlates with reduced rumination and improved mood. Connections between emotional centres (such as the amygdala and hippocampus) and prefrontal “thinking” areas also appear to become healthier, which is consistent with improved emotional regulation. These changes in brain function are measurable biomarkers which support the subjective improvements. They provide objective evidence for the idea that psilocybin frees the brain from rigid, pathological patterns and enables it to function in a more flexible and integrated way.

Conclusion and key findings

Psilocybin therapy exerts its therapeutic effect via a dual carriageway: a psychological-emotional one and a neurobiological-biochemical one. Firstly, psilocybin facilitates a profound emotional processing. It helps patients to confront their fear, grief and trauma and to let go by promoting acceptance and breaking avoidance patterns. The experience of “letting go” during a psilocybin session proves crucial – acceptance and surrender lead to emotional breakthroughs accompanied by a lasting reduction in symptoms. At the same time, a range of neurobiological changes which underpin these psychological processes. Psilocybin increases the neurotrophic factor BDNF and, via both 5-HT₂A receptors and direct TrkB binding, activates powerful processes of neuroplasticity, enabling the brain to form new connections and healthier patterns. Cellular stress response systems, such as SIRT1, are also activated, which counteract oxidative stress and ageing. Furthermore, there is evidence that psilocybin has beneficial systemic effects has – from reducing inflammatory markers to protecting pancreatic β-cells under metabolic stress. All these factors together increase the resilience of the brain and the body.

In short, psilocybin therapy owes its effectiveness to the unique interplay between the mind and the body: it opens people up emotionally, enabling them to process fears and trauma under safe supervision, whilst also restructuring the brain at a molecular level to consolidate this process of change. Recent peer-reviewed studies since 2020 confirm that this integrated approach results in remarkable and lasting therapeutic benefits for a range of complex conditions. The findings to date justify the growing scientific enthusiasm for psilocybin therapy as a breakthrough in the treatment of mental disorders – an approach that both the heart as the brain heals.

It works better for me because I’m able to let go of certain emotions during a trip that might otherwise be harder to let go of.